GLP-2

GLP-2 30 mg – High-Purity Research Peptide (GIP/GLP-1 Dual Agonist)

CAS Number: 2023788-19-2
Molecular Formula: C₂₂₅H₃₄₁N₅₁O₇₀
Molar Mass: ~4813.5 g/mol
Purity: ≥98% (HPLC)
Form: Lyophilized powder
Peptide Content: 30 mg per vial
Synonyms: LY3298176, Dual GIP/GLP-1 Receptor Agonist

Product Overview

GLP-2 is a novel, long-acting dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. As a synthetic peptide, Tirzepatide has garnered significant interest in metabolic and endocrine research, particularly in models of glucose regulation, insulin sensitivity, and energy homeostasis.

CombatResearch.io offers GLP-2 30 mg in a high-purity lyophilized format, suitable for controlled in vitro and preclinical research settings. Each batch is QC-tested for identity and integrity using HPLC and mass spectrometry, ensuring consistent and reproducible results.

Key Research Applications

• Investigation of incretin-based signaling pathways

• Studies on insulin secretion and glucose homeostasis

• Metabolic syndrome and obesity-related model research

• Dual receptor agonist pharmacodynamics and pharmacokinetics

• Structure-activity relationship (SAR) in peptide therapeutics

Storage & Reconstitution

• Store at –20°C for long-term stability

• Reconstitute with sterile water or appropriate buffer under aseptic conditions

• Use immediately after reconstitution or aliquot and freeze

Regulatory Disclaimer

For Research Use Only. Not for Human or Veterinary Use.
GLP-2 offered by CombatResearch.io is intended strictly for scientific laboratory research. This compound is not approved by the FDA and is not a drug, food additive, or dietary supplement. It must not be used in humans or animals and must be handled by qualified professionals in compliance with local, state, and federal regulations.

Note: All product information is provided for research and informational purposes only. It does not constitute endorsement or recommendation for clinical or therapeutic use.